Tag: Vte prophylaxis

Approximately 350,000 to 600,000 Americans are affected by venous thromboembolism (VTE) each year, making preventative care essential. Understanding which of the following is used for VTE prophylaxis is crucial for both medical professionals and patients to mitigate this serious risk effectively.

Up to 900,000 people in the United States are affected by venous thromboembolism (VTE) each year, making prevention critical [1.9.1]. So, what drugs are approved for VTE prophylaxis? Key medications include heparins and direct oral anticoagulants (DOACs) [1.3.3, 1.4.1].

Betrixaban is its own generic name, but it was formerly marketed under the brand name Bevyxxa. A notable fact about this medication is that it was voluntarily withdrawn from the market by its manufacturer in April 2020 for business reasons, not due to safety concerns.

In June 2020, Portola Pharmaceuticals conducted a market withdrawal of Betrixaban (Bevyxxa) for business reasons, not due to specific safety or quality concerns. This article explores the clinical trial data, market challenges, and regulatory hurdles that answer the question: **Why was Betrixaban discontinued?**